- Global Pharma News & Resources

RareChannels Announces New Chief Commercial Advisor

MOUNT VERNON, Ill., March 6, 2019 /PRNewswire/ -- Carol J. Dickerson, Pharm D, Founder & CEO of CCA Channels, Inc, announces the addition of Lyne Fortin, former Senior Vice-President & Chief Commercial Officer of Theratechnologies Inc., as RareChannels Chief Commercial Advisor.  At Theratechnologies, Lyne built the North American commercial capabilities, including managed care and patient access, to bring to market drugs addressing unmet medical needs for small populations of patients, as well as contributing to development of the European market. Over the five years of her tenure, market capitalization grew approximately from $35M to $700M.

Lyne commented, "If there was ever a time where rare diseases need a catalyst, it is now and that is exactly what RareChannels represents with its unparalleled B2B approach."

Carol stated, "When I began drawing out the leadership team wish-list, without a doubt Lyne Fortin was my holy grail.  I have never worked with someone who could masterfully lead & manage so many complicated and team-based projects.  When she announced her retirement from Theratechnologies, I seized the opportunity to approach her. We worked closely together for 3 years, building and managing complex and strategic commercialization processes in the supply chain and market access for rare patient populations in HIV.  Lyne and I not only managed well together, we also see the same unsustainable situation in rare diseases as well as the value this solution brings which lead her to say "yes" to RareChannels. We truly want cures and therapies brought to the globe faster and cheaper."

The $250B consulting industry, with their traditional approaches for brand new markets that have no, or very few paths built, are sub-optimal in many respects. In the first 2 months of 2019 alone, there have been $146B in big pharma acquisitions of rare disease companies, and this phenomenon does not solve the underlying issue. It, instead, compounds it by force-fitting rare diseases into the same mainstream pattern, whereas RareChannels is positioned to deliver valuable niche content-experts and solutions in B2B connections.  We see everyone in the Rare Disease space as potential partners in this wave of disruption.  There are so many experienced niche-consultants and specialty firms that can be empowered by a targeted marketing channel.

RareChannels has been invited to present on March 7 at  youngStartup Ventures "Venture Summit West 2019", in San Francisco, CA.

View original content:

SOURCE Rare Channel Solutions, LLC

Editor Details

Last Updated: 06-Mar-2019